Vericel Corp VCEL
We take great care to ensure that the data presented and summarized in this overview for Vericel Corp is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding VCEL
View all-
Black Rock Inc. New York, NY8.06MShares$321 Million0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA3.52MShares$140 Million0.0% of portfolio
-
State Street Corp Boston, MA2.81MShares$112 Million0.0% of portfolio
-
William Blair Investment Management, LLC Chicago, IL2.21MShares$88.1 Million0.19% of portfolio
-
Conestoga Capital Advisors, LLC2.18MShares$86.7 Million1.1% of portfolio
-
Brown Capital Management LLC Baltimore, MD1.95MShares$77.8 Million2.65% of portfolio
-
Geneva Capital Management LLC1.95MShares$77.6 Million1.06% of portfolio
-
Congress Asset Management CO1.49MShares$59.6 Million0.33% of portfolio
-
Gw&K Investment Management, LLC Boston, MA1.29MShares$51.4 Million0.36% of portfolio
-
Bnp Paribas Asset Management Holding S.A.1.27MShares$50.5 Million0.1% of portfolio
Latest Institutional Activity in VCEL
Top Purchases
Top Sells
About VCEL
Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in the United States. The company markets autologous cell therapy products comprising MACI, an autologous cellularized scaffold product for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; and Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns. Its preapproval stage product is NexoBrid, a registration-stage biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns. The company was formerly known as Aastrom Biosciences, Inc. Vericel Corporation was incorporated in 1989 and is headquartered in Cambridge, Massachusetts.
Insider Transactions at VCEL
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Dec 03
2025
|
Paul K Wotton |
SELL
Open market or private sale
|
Direct |
2,500
-8.9%
|
$92,500
$37.83 P/Share
|
|
Dec 02
2025
|
Paul K Wotton |
SELL
Open market or private sale
|
Direct |
2,500
-8.17%
|
$92,500
$37.97 P/Share
|
|
Dec 02
2025
|
Jonathan Mark Hopper Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
1,652
-2.42%
|
$64,428
$39.14 P/Share
|
|
Dec 02
2025
|
Jonathan Mark Hopper Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
1,652
+2.36%
|
$29,736
$18.0 P/Share
|
|
Nov 11
2025
|
Michael Halpin Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
2,642
-14.22%
|
$105,680
$40.41 P/Share
|
|
Nov 11
2025
|
Michael Halpin Chief Operating Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
2,642
+12.45%
|
$42,272
$16.66 P/Share
|
|
Nov 10
2025
|
Kevin F Mclaughlin |
SELL
Open market or private sale
|
Direct |
7,000
-31.67%
|
$266,000
$38.59 P/Share
|
|
Nov 10
2025
|
Kevin F Mclaughlin |
BUY
Exercise of conversion of derivative security
|
Direct |
7,000
+24.06%
|
$14,000
$2.63 P/Share
|
|
Nov 06
2025
|
Michael Halpin Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
7,358
-31.59%
|
$294,320
$40.47 P/Share
|
|
Nov 06
2025
|
Michael Halpin Chief Operating Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
7,358
+24.01%
|
$117,728
$16.66 P/Share
|
|
Sep 30
2025
|
Jonathan Siegal Principal Accounting Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
370
-15.16%
|
$11,470
$31.47 P/Share
|
|
Sep 30
2025
|
Jonathan Siegal Principal Accounting Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
938
+27.77%
|
-
|
|
Sep 02
2025
|
Jonathan Mark Hopper Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
10,000
-13.1%
|
$350,000
$35.77 P/Share
|
|
Sep 02
2025
|
Jonathan Mark Hopper Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
10,000
+11.58%
|
$180,000
$18.0 P/Share
|
|
Aug 06
2025
|
Kevin F Mclaughlin |
SELL
Open market or private sale
|
Direct |
7,000
-31.67%
|
$245,000
$35.92 P/Share
|
|
Aug 06
2025
|
Kevin F Mclaughlin |
BUY
Exercise of conversion of derivative security
|
Direct |
7,000
+24.06%
|
$14,000
$2.76 P/Share
|
|
Jul 22
2025
|
Karen Mahoney Chief Human Resources Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
771
-29.37%
|
$28,527
$37.98 P/Share
|
|
Jul 22
2025
|
Karen Mahoney Chief Human Resources Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
2,625
+50.0%
|
-
|
|
Jun 02
2025
|
Jonathan Mark Hopper Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
10,000
-13.12%
|
$400,000
$40.09 P/Share
|
|
Jun 02
2025
|
Jonathan Mark Hopper Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
10,000
+11.6%
|
$180,000
$18.0 P/Share
|
Last 12 Months Summary
| Exercise of conversion of derivative security | 380K shares |
|---|
| Open market or private sale | 250K shares |
|---|---|
| Payment of exercise price or tax liability | 40K shares |